Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the oral cavity, paranasal sinuses, nasopharynx, larynx, hypopharynx, or oropharynx~  * Medically or surgically inoperable disease or patient refuses surgery~ * Recurrent disease~* Previously irradiated disease meeting the following criteria:~  * Prior radiotherapy completed \> 6 months from re-irradiation~ * Prior radiotherapy in the region of the study cancer that would result in overlap of radiation therapy fields~ * Majority of the recurrent tumor volume (\> 50%) received prior radiotherapy dose of 30-75 Gy~* No distant metastatic disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 60 days after completion of study treatment~* No prior allergic reaction to study drugs~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior surgical resection of the recurrent primary tumor and/or regional lymphatics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cetuximab (Type: EXPERIMENTAL): Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5

Based on this trial design, predict the completion outcome and termination type (if applicable).